


Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

 2720 Accredited to ISO/IEC 17025:2017	Abbott Toxicology Limited	
	Issue No: 040 Issue date: 24 July 2020	
	21 Blacklands Way Abingdon Business Park Abingdon Oxfordshire OX14 1DY	Contact: Martyn Rogers Tel: +44 (0)1235 861483 Fax: +44 (0)1235 835607 E-Mail: martyn.rogers@abbott.com Website: www.aleretoxicology.co.uk
Testing performed by the Organisation at the locations specified		

Locations covered by the organisation and their relevant activities

Laboratory locations:

Location details	Activity	Location code
Address 21 Blacklands Way Abingdon Business Park Abingdon Oxfordshire OX14 1DY	Local contact: Martyn Rogers Tel: +44 (0) 1235 861483 E-mail: martyn.rogers@abbott.com	Management, quality, laboratory testing and reporting activities A

Site activities performed away from the locations listed above:

Location details	Activity	Location code
Address Charterhouse II Links Business Park St Mellons CF3 0LT	Local contact: Martyn Rogers Tel: +44 (0) 1235 861483 E-mail: martyn.rogers@abbott.com	Reporting activities only B



2720
Accredited to
ISO/IEC 17025:2017

Schedule of Accreditation
issued by
United Kingdom Accreditation Service
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Abbott Toxicology Limited
Issue No: 040 Issue date: 24 July 2020

Testing performed by the Organisation at the locations specified

DETAIL OF ACCREDITATION

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used	Location Code
BODY FLUIDS and TISSUES	<u>Workplace Drugs Analysis/Medical and Legal Analysis</u>		
Oral Fluid (extracted from Concateno Certus collection device)	Presumptive screening for the presence of the following drug(s) or drug group(s) (cut-off limit): Cannabinoids (1ng/ml)	Documented in-house method A4002 using ELISA (Enzyme Linked Immunosorbent Assay)	A
	Amphetamines (50ng/ml; 10ng/ml) Methamphetamines (20ng/ml) Cocaine (5ng/ml) Methadone (10ng/ml) Opiates (10ng/ml) 6-monoacetylmorphine (6-MAM) (1ng/ml)	Documented in-house method A3033 using Liquid EIA Screening	A
Oral Fluid (extracted from Certus collection device)	Confirmation and quantitative analysis of the following drugs (cut-off limit/ concentration range): Amphetamines: Amphetamine (5 ng/ml/ 0.5-250 ng/ml) Methamphetamine (5 ng/ml/ 0.5-250 ng/ml) Methylenedioxyamphetamine (MDA) (5 ng/ml /0.5-250 ng/ml) Methylenedioxyethylamphetamine (MDEA) (5 ng/ml / 0.5-250 ng/ml) Methylenedioxymethylamphetamine (MDMA) (5 ng/ml / 0.5-250 ng/ml) N-methyl-1,3-benzodioxolylbutanamine (MBDB) (5 ng/ml / 0.5-250 ng/ml) Benzodiazepines: Chlordiazepoxide (2 ng/ml / 0.5-250 ng/ml) Desmethyldiazepam (Nordiazepam) (2 ng/ml /0.5-250 ng/ml) Diazepam (2 ng/ml / 0.5-250 ng/ml) Flurazepam (2 ng/ml / 0.5-250 ng/ml) Midazolam (2 ng/ml / 0.5-250 ng/ml) Nitrazepam (2 ng/ml / 0.5-250 ng/ml) Oxazepam (2 ng/ml / 0.5-250 ng/ml) Temazepam (2 ng/ml / 0.5-250 ng/ml)	Documented in-house method A5037 using micro-elution and LC-MS/MS	A



2720
Accredited to
ISO/IEC 17025:2017

Schedule of Accreditation
issued by
United Kingdom Accreditation Service
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Abbott Toxicology Limited
Issue No: 040 Issue date: 24 July 2020

Testing performed by the Organisation at the locations specified

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used	Location Code
BODY FLUIDS and TISSUES Oral Fluid (extracted from Certus collection device)	<u>Workplace Drugs Analysis/Medical and Legal Analysis</u> Confirmation and quantitative analysis of the following drugs (cut-off limit/ concentration range): Opiates: 6-monoacetylmorphine (6-MAM) (1 ng/ml / 0.5-250 ng/ml) 6-acetylcodeine (5 ng/ml / 0.5-250 ng/ml) Codeine (5 ng/ml /0.5-250 ng/ml) Dihydrocodeine (5 ng/ml /0.5-250 ng/ml) Morphine (5 ng/ml /0.5-250 ng/ml) Methadone group: Methadone (5 ng/ml /0.5-250 ng/ml) 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) (1 ng/ml / 0.5-250 ng/ml) Cocaine group: Benzoylecgonine (2 ng/ml / 0.5-250 ng/ml) Cocaethylene (2 ng/ml / 0.5-250 ng/ml) Cocaine (2 ng/ml / 0.5-250 ng/ml) Norcocaine (2 ng/ml / 0.5-250 ng/ml) Anhydroecgonine methyl ester (AEME) (2 ng/ml / 0.5-250 ng/ml) Cannabis: Δ-9 tetrahydrocannabinol (0.5 ng/ml / 0.1-50 ng/ml) Ketamine (2 ng/ml / 0.5-250 ng/ml) Mephedrone (2 ng/ml / 0.5-250 ng/ml)	Documented in-house method A5037 using micro-elution and LC-MS/MS	A
Oral Fluid (extracted from DDS2/SoToxa collection device)	Buprenorphine group: Buprenorphine (0.5 ng/ml / 0.1-25 ng/ml) Norbuprenorphine (0.5 ng/ml / 0.1-25 ng/ml) Propoxyphene (5 ng/ml / 1-250 ng/ml)	Documented in-house method A5039 using micro-elution and LC-MS/MS	A
Oral Fluid (extracted from DDS2/SoToxa collection device)	Cocaine group: Benzoylecgonine (8 ng/ml /1-500 ng/ml) Cocaine (8 ng/ml / 1-500 ng/ml)	Documented in-house method A5027 using LC-MS/MS	A



2720
Accredited to
ISO/IEC 17025:2017

Schedule of Accreditation
issued by
United Kingdom Accreditation Service
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Abbott Toxicology Limited
Issue No: 040 Issue date: 24 July 2020

Testing performed by the Organisation at the locations specified

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used	Location Code
BODY FLUIDS and TISSUES	<u>Workplace Drugs Analysis/Medical and Legal Analysis</u>		
Oral Fluid (extracted from DDS2/SoToxa collection device)	Confirmation and quantitative analysis of the following drugs (cut-off limit/ concentration range): Opiates group: 6-monoacetylmorphine (6-MAM) (4 ng/ml / 0.5-250 ng/ml) Codeine (15 ng/ml / 2.5-1250 ng/ml) Dihydrocodeine (15 ng/ml / 2.5-1250 ng/ml) Morphine (15 ng/ml / 2.5-1250 ng/ml)	Documented in-house method A5027 using LC-MS/MS	A
Hair	Presumptive screening for the presence of the following drug(s) or drug group(s) (cut-off limit): Amphetamine (0.2 ng/mg) Benzodiazepines (Excluding Oxazepam) (0.2 ng/mg) Cannabis (0.05 ng/mg) Cocaine (0.5ng/mg) Ketamine (0.2 ng/mg) Methadone (0.2 ng/mg) Methamphetamines (0.2 ng/mg) Opiates (0.2 ng/mg)	Documented in-house method A5034 using LC-MS/MS	A
Hair	Confirmation and quantitative analysis of the following drugs (cut-off limit/ concentration range): Ethyl Glucuronide (EtG) (30 pg/mg / 15-300 pg/mg)	Documented in-house method A5047 using LCMS/MS	A
	Fatty Acid Ethyl Ester (FAEE's): Ethyl Palmitate - 0-3cm (0.35 ng/mg / 0.25-5 ng/mg) - >3cm-6cm (0.45 ng/mg /0.25-5 ng/mg)	Documented in-house method A5048 using LCMS/MS	A



2720
Accredited to
ISO/IEC 17025:2017

Schedule of Accreditation
issued by
United Kingdom Accreditation Service
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Abbott Toxicology Limited
Issue No: 040 Issue date: 24 July 2020

Testing performed by the Organisation at the locations specified

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used	Location Code
BODY FLUIDS and TISSUES	<u>Workplace Drugs Analysis/Medical and Legal Analysis</u>		
Hair	<p>Confirmation and quantitative analysis of the following drugs (cut-off limit/ concentration range):</p> <p>Amphetamines group: Amphetamine (0.2 ng/mg / 0.05-12.5 ng/mg) Methamphetamine (0.2 ng/mg / 0.05-12.5 ng/mg) Methylenedioxyamphetamine (MDA) (0.2 ng/mg / 0.05-12.5 ng/mg) Methylenedioxyethylamphetamine (MDEA) (0.2 ng/mg / 0.05-12.5 ng/mg) Methylenedioxymethylamphetamine (MDMA) (0.2 ng/mg / 0.05-12.5 ng/mg) N-methyl-1,3-benzodioxolylbutanamine (MBDB) (0.2 ng/mg / 0.05-12.5 ng/mg)</p> <p>Benzodiazepines group: Chlordiazepoxide (0.2 ng/mg / 0.05-12.5 ng/mg) Desmethyldiazepam (Nordiazepam) (0.2 ng/mg / 0.05-12.5 ng/mg) Diazepam (0.2 ng/mg / 0.05-12.5 ng/mg) Flurazepam (0.2 ng/mg / 0.05-12.5 ng/mg) Midazolam (0.2 ng/mg / 0.05-12.5 ng/mg) Nitrazepam (0.2 ng/mg / 0.05-12.5 ng/mg) Temazepam (0.2 ng/mg / 0.05-12.5 ng/mg)</p> <p>Cannabis group: δ-9 tetrahydrocannabinol (0.05 ng/mg / 0.005-1.25 ng/mg) Cannabis metabolite (11-nor-Δ-9 tetrahydrocannabinol carboxylic acid) (0.2 pg/mg / 0.05-12.5 pg/mg)</p> <p>Cocaine group: Anhydroecgonine methyl ester (AEME) (0.5 ng/mg / 0.025-12.5 ng/mg) Benzoylecgonine (0.05 ng/mg / 0.025-12.5 ng/mg) Cocaethylene (0.05 ng/mg / 0.025-12.5 ng/mg) Cocaine (0.5 ng/mg / 0.025-12.5 ng/mg) Norcocaine (0.05 ng/mg / 0.025-12.5 ng/mg)</p>	Documented in-house method A5028 using LC-MS/MS	A



2720
Accredited to
ISO/IEC 17025:2017

Schedule of Accreditation
issued by
United Kingdom Accreditation Service
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Abbott Toxicology Limited
Issue No: 040 Issue date: 24 July 2020

Testing performed by the Organisation at the locations specified

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used	Location Code
BODY FLUIDS and TISSUES Hair	<u>Workplace Drugs Analysis/Medical and Legal Analysis</u> Confirmation and quantitative analysis of the following drugs (cut-off limit/ concentration range): Methadone group: Methadone (0.2 ng/mg / 0.05-12.5 ng/mg) 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) (0.2 ng/mg / 0.05-12.5 ng/mg) Opiates group: 6-monoacetylmorphine (6-MAM) (0.2 ng/mg / 0.05-12.5 ng/mg) 6-Acetylcodeine (0.2 ng/mg / 0.05-12.5 ng/mg) Heroin (0.2 ng/mg / 0.05-12.5 ng/mg) Codeine (0.2 ng/mg / 0.05-12.5 ng/mg) Dihydrocodeine (0.2 ng/mg / 0.05-12.5 ng/mg) Morphine (0.2 ng/mg / 0.05-12.5 ng/mg) Ketamine (0.2 ng/mg /0.05-12.5 ng/mg) Mephedrone (0.2 ng/mg /0.05-12.5 ng/mg)	Documented in-house method A5028 using LC-MS/MS	A
END			